<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Yellow fever: Epidemiology, clinical manifestations, and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Yellow fever: Epidemiology, clinical manifestations, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Yellow fever: Epidemiology, clinical manifestations, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Annelies Wilder-Smith, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 01, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Yellow fever is a mosquito-borne viral hemorrhagic fever with a high case-fatality rate. Clinical manifestations include hepatic dysfunction, renal failure, coagulopathy, and shock. Travelers to tropical regions of South America and sub-Saharan Africa where the disease is endemic are at risk for acquisition of infection and require immunization.</p><p>Issues related to virology, pathogenesis, epidemiology, clinical manifestations, and diagnosis of yellow fever will be reviewed here. Issues related to the treatment and prevention of yellow fever are discussed separately. (See  <a class="medical medical_review" href="/d/html/129108.html" rel="external">"Yellow fever: Treatment and prevention"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">VIROLOGY, PATHOGENESIS, AND HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>Yellow fever is the prototype member of the family Flaviviridae, a group of small (40 to 60 nm), enveloped, positive-sense, single-stranded RNA viruses that replicate in the cytoplasm of infected cells. Yellow fever virus is a single serotype and is antigenically conserved, so the vaccine protects against all strains of the virus. At the nucleotide sequence level, it is possible to distinguish seven major genotypes representing West Africa (two genotypes), Central-East Africa and Angola (three genotypes), and South America (two genotypes) [<a href="#rid1">1,2</a>]. </p><p>The yellow fever virus re-emerged in large outbreaks in Africa (2015 to 2016) and Brazil (2016 to 2018). Phylogenetic studies demonstrated that the 2016 strains were similar to Angola 1971 strains and only three amino acid changes were new to other lineages [<a href="#rid3">3</a>]. In Brazil, cocirculation of two distinct yellow fever virus clades occurring in humans and nonhuman primates suggests multiple sylvatic transmission cycles [<a href="#rid4">4</a>]. </p><p>Humans are highly susceptible to infection and disease. Most nonhuman primate species are susceptible to infection, and some species of nonhuman primates develop clinical manifestations.</p><p>An infected female mosquito inoculates approximately 1000 to 100,000 virus particles intradermally during blood feeding. Virus replication begins at the site of inoculation, probably in dendritic cells in the epidermis, and spreads through lymphatic channels to regional lymph nodes. Lymphoid cells, particularly monocyte-macrophages and large histiocytes, appear to be the preferred cell types for primary replication. The virus reaches other organs via the lymph and then the bloodstream, seeding other tissues. Large amounts of virus are produced in the liver, lymph nodes, and spleen and are released into the blood. During the viremic phase (days three to six), infection may be transmitted to blood-feeding mosquitoes.</p><p>Yellow fever is characterized by hepatic dysfunction, renal failure, coagulopathy, and shock [<a href="#rid5">5-8</a>]. The midzone of the liver lobule is principally affected, with sparing of cells bordering the central vein and portal tracts [<a href="#rid9">9</a>]. Viral antigen localizes to the midzone, indicating that it is the site of direct viral injury. Very high virus loads have been found in the liver and spleen of fatal cases [<a href="#rid10">10</a>].</p><p>Injury to hepatocytes is characterized by eosinophilic degeneration with condensed nuclear chromatin (Councilman bodies) rather than by the ballooning and rarefaction necrosis seen in viral hepatitis. Liver cell death is due to apoptosis. Hepatocytes in the midzone of the liver lobule express Fas ligand, and lymphocytes infiltrating the liver mediate apoptosis. Inflammatory cells, mainly CD4+ cells, are present in low numbers; smaller numbers of NK and CD8+ cells are present [<a href="#rid11">11,12</a>]. There is no disruption of the reticular architecture of the liver. In nonfatal cases, healing is complete without postnecrotic fibrosis. In fatal cases, approximately 80 percent of hepatocytes undergo coagulative necrosis.</p><p>Renal damage is characterized by eosinophilic degeneration and fatty change of renal tubular epithelium without inflammation. These findings are believed to be a result of both direct viral injury and nonspecific changes due to hypotension and the hepatorenal syndrome [<a href="#rid7">7</a>].</p><p>Focal injury to the myocardium, characterized by cell degeneration and fatty change, is the result of viral replication.</p><p>The hemorrhagic diathesis in yellow fever is due to decreased synthesis of vitamin K-dependent coagulation factors by the liver, disseminated intravascular coagulation, and platelet dysfunction.</p><p>The late phase of the disease is characterized by circulatory shock. The underlying mechanism may be cytokine dysregulation, as in the sepsis syndrome. In a series of patients with fatal yellow fever, levels of proinflammatory cytokines (interleukin [IL]-6, IL-1 receptor antagonist, tumor necrosis factor [TNF]-alpha, and interferon-inducible protein-10) were elevated compared with patients with nonfatal yellow fever [<a href="#rid13">13</a>]. Patients dying of yellow fever have cerebral edema at autopsy, probably the result of microvascular dysfunction. Large amounts of complement-fixing antigen (presumably NS1) have been found in blood of severely ill yellow fever patients [<a href="#rid14">14</a>].</p><p>Some nonhuman primate species develop fatal infection with features similar to the disease in humans [<a href="#rid7">7</a>]. A model of yellow fever infection in hamsters has been described [<a href="#rid15">15,16</a>]. Clinical, immunologic, and pathologic features resemble human infection, suggesting that this model might serve to increase the understanding of the pathogenesis of infection and to explore possible treatments. Interferon-alpha/beta receptor-deficient mice are also susceptible to viscerotropic infection [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H1301185932"><span class="h2">Geographic distribution</span><span class="headingEndMark"> — </span>Yellow fever occurs in tropical regions of sub-Saharan Africa and South America; it is an epidemic disease problem of considerable magnitude [<a href="#rid18">18,19</a>]. The incidence of endemic disease is not well established, but approximately 1 percent of individuals with severe hepatitis in endemic areas of Africa may be caused by yellow fever [<a href="#rid20">20</a>]. An estimate from serologic and epidemiologic data concluded that there were 130,000 cases with viscerotropic disease and 78,000 deaths in Africa in 2013 [<a href="#rid21">21</a>].</p><p>The incidence of yellow fever in Africa varies widely, and the disease occurs in epidemics [<a href="#rid18">18</a>]. A large <em>Aedes aegypti</em>–borne epidemic occurred in Angola and neighboring Democratic Republic of the Congo in south/central Africa between December 2015 and July 2016 with over 2930 confirmed or suspected cases and 253 deaths and resulting in the emergency distribution of 30 million doses of vaccine [<a href="#rid22">22-24</a>]. Mosquito-borne epidemics in Africa occur where large human populations reside in high density and immunization coverage is low. The highest number of outbreaks has occurred in West Africa, but this situation is changing due to a concerted effort to undertake mass immunization campaigns in that region. Human-to-human transmission in the absence of the mosquito has not been reported.</p><p>Fewer cases occur in South America than in Africa because transmission occurs from enzootic sources (principally from monkey to human via mosquito vectors), the vector density is relatively low, and vaccination coverage is relatively high (80 to 90 percent in endemic areas of South America). In typical years, there are several hundred cases officially notified, but in epidemic years up to 5000 cases are reported. Between 2016 and 2018, rapid expansion of a severe sylvatic yellow fever virus outbreak occurred in southeastern Brazil. This outbreak reached one of the most populated metropolitan areas in Brazil that had been yellow fever-free for more than 70 years [<a href="#rid25">25</a>]. Between January and March 2018, one report noted 79 patients with severe yellow fever in Sao Paolo required intensive care [<a href="#rid26">26</a>].</p><p>In Africa and South America, only a small proportion of cases is officially recorded because the disease often occurs in remote areas, recognition of outbreaks is delayed, and diagnostic facilities are limited. In Africa, reports of outbreaks in the 1980s noted the incidence of yellow fever infection to be 20 to 40 percent, the incidence of severe disease to be 3 to 5 percent, and the case-fatality rate to be 20 to 30 percent. In contrast, case-fatality rates in South America are consistently 50 to 60 percent. It is uncertain whether these disparities reflect reporting artifact, a real difference in virus strain virulence, and/or differing genetic susceptibility of the human populations. A racial difference in susceptibility is likely, supported by an analysis of epidemiologic data from an 1878 epidemic in Tennessee, in which yellow fever attack rates were similar in the White and non-White populations of the city, but the case-fatality rate was 6.8-fold higher in White persons [<a href="#rid27">27</a>].</p><p>Yellow fever epidemics have never been reported in Asia, and introduction to that region could have devastating effects since there is no background of specific immunity, and the urban vector (<em>Aedes aegypti</em>) is prevalent. In the context of the 2016 yellow fever outbreak in Angola, at least 11 Chinese workers developed yellow fever upon travel home to China, illustrating the danger of introduction and potential secondary spread [<a href="#rid28">28</a>].</p><p>Prior to the reports among travelers from Angola, yellow fever in expatriates and travelers to and from Africa and South America had been rare; since the introduction of vaccination after World War II, ten cases had been recorded up to the time of the 2016 Angolan outbreak [<a href="#rid10">10,29-33</a>]. During the Angola outbreak, 11 Chinese construction workers were infected while working in Angola and subsequently exported the virus upon return to China; this was the first documented exportation of yellow fever into Asia. Subsequent analyses showed that the majority of Chinese workers in Angola had not been vaccinated [<a href="#rid34">34</a>]. The outbreak in Brazil resulted in more exportation of yellow fever via travelers than in the previous decades [<a href="#rid35">35</a>]. (See <a class="local">'Outbreak in South America'</a> below.)</p><p>Changes in human demography, particularly expansion of urban populations throughout the tropics, expansion of air travel, and rapid spread of other viruses (dengue, Zika, chikungunya) transmitted between humans by urban <em>Ae. aegypti </em>throughout the southern hemisphere illustrate the global dangers associated with exportation and spread of yellow fever.</p><p class="headingAnchor" id="H96762949"><span class="h3">Outbreak in South America</span><span class="headingEndMark"> — </span>An ongoing yellow fever outbreak in Brazil began in December 2016 [<a href="#rid35">35-37</a>]. Between July 1, 2017, and February 16, 2018, 464 confirmed human cases of yellow fever were reported in Brazil, including 154 deaths [<a href="#rid37">37</a>]. In March 2018, the Brazilian health ministry issued a recommendation for universal yellow fever vaccination in Brazil [<a href="#rid37">37</a>].</p><p>Since January 2018, 10 travel-related cases have been reported in international travelers returning from Brazil, including four deaths; none of the 10 travelers had received yellow fever vaccination [<a href="#rid35">35</a>]. In March 2018, the United States Centers for Disease Control and Prevention issued an <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwwwnc.cdc.gov%2Ftravel%2Fnotices%2Falert%2Fyellow-fever-brazil&amp;token=MmgyN0jwL1Npa11Wu%2BcskaJdeq22vsN4NOWCSkViONLRDmtvJtPOcMtP%2Bd%2FioXPIGGgMTgwHHKHF71VCSUAxTGyGKOhpDgkW1lP%2FjvBV4Tg%3D&amp;TOPIC_ID=3032" target="_blank">advisory</a> which expanded the regions within Brazil for which travelers should receive <a class="drug drug_general" data-topicid="10051" href="/d/drug information/10051.html" rel="external">yellow fever vaccine</a> [<a href="#rid38">38-40</a>]. In 2018, five countries in the Americas reported confirmed cases of yellow fever: Bolivia, Brazil, Colombia, French Guiana, and Peru. As of September 2019, three countries in the Region of the Americas reported yellow fever (Bolivia, Brazil, and Peru) [<a href="#rid41">41</a>]. </p><p class="headingAnchor" id="H4"><span class="h2">Transmission cycles</span><span class="headingEndMark"> — </span>The primary transmission cycle involves monkeys and daytime biting mosquitoes (<em>Aedes</em> species in Africa, <em>Haemagogus</em> species in South America).</p><p>In Africa, a wide array of <em>Aedes</em> vectors is responsible for transmission. During the rainy season, the virus circulates via mosquitoes in the savanna vegetational zone in proximity to human settlements. Both humans and nonhuman primates can be hosts in the transmission cycle, and the rate of virus transmission may accelerate to reach epidemic levels. <em>Aedes aegypti</em>, a common domestic mosquito that can breed in containers used to store potable water in heavily settled areas, is capable of serving as an epidemic vector with humans as the intermediate viremic hosts (so-called "urban yellow fever").</p><p>In South America, the larval development of mosquitoes occurs in areas such as tree holes containing rainwater. Persons entering forested areas are at risk of infection (so-called "jungle yellow fever"); this accounts for the predominance of cases among young males engaged in forest clearing and agriculture. In the 1970s, the <em>Aedes aegypti</em> mosquito reinvaded areas of South America where it previously had been eradicated, increasing the risk that urban yellow fever may re-emerge. The first well-documented instance of an urban-cycle epidemic since 1942 occurred in Paraguay in 2008 [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The clinical spectrum of yellow fever includes [<a href="#rid43">43</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Subclinical infection</p><p class="bulletIndent1"><span class="glyph">●</span>Abortive, nonspecific febrile illness without jaundice</p><p class="bulletIndent1"><span class="glyph">●</span>Life-threatening disease with fever, jaundice, renal failure, and hemorrhage</p><p></p><p>Yellow fever affects all ages, but disease severity and lethality is highest in older adults. The onset of illness appears abruptly three to six days (median 4.3 days) after the bite of an infected mosquito [<a href="#rid44">44</a>]. The classical illness is characterized by three stages:</p><p class="bulletIndent1"><span class="glyph">●</span>Period of infection</p><p class="bulletIndent1"><span class="glyph">●</span>Period of remission</p><p class="bulletIndent1"><span class="glyph">●</span>Period of intoxication</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Period of infection</span><span class="headingEndMark"> — </span>The period of infection consists of viremia, which lasts for three to four days. The patient is febrile and complains of generalized malaise, headache, photophobia, lumbosacral pain, pain in the lower extremities, myalgia, anorexia, nausea, vomiting, restlessness, irritability, and dizziness [<a href="#rid45">45</a>]. Symptoms and signs are relatively nonspecific; at this phase, it is virtually impossible to distinguish yellow fever from other acute infections.</p><p>On physical examination, the patient appears acutely ill with flushed skin, reddening of the conjunctivae and gums, and epigastric tenderness. Enlargement of the liver with tenderness may be present. The tongue is characteristically red at the tip and sides with a white coating in the center. The pulse rate is slow relative to the height of the fever (Faget's sign). The temperature is typically 39ºC but may rise as high as 41ºC.</p><p>Laboratory abnormalities include leukopenia (1500 to 2500 per microL) with relative neutropenia; leukopenia occurs rapidly after the onset of illness. Serum transaminase levels start to rise 48 and 72 hours after onset of illness, prior to the appearance of jaundice. The degree of liver enzyme abnormalities at this stage may predict the severity of hepatic dysfunction later in the illness [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Period of remission</span><span class="headingEndMark"> — </span>A period of remission lasting up to 48 hours may follow the period of infection, characterized by the abatement of fever and symptoms. Patients with abortive infections recover at this stage. Approximately 15 percent of individuals infected with yellow fever virus enter the third stage of the disease.</p><p class="headingAnchor" id="H8"><span class="h2">Period of intoxication (severe yellow fever)</span><span class="headingEndMark"> — </span>The period of intoxication begins on the third to sixth day after the onset of infection with return of fever, prostration, nausea, vomiting, epigastric pain, jaundice, oliguria, and hemorrhagic diathesis. The viremia disappears at this stage and antibodies appear in the blood, although ongoing viremia has also been reported [<a href="#rid47">47</a>]. Patients with viral loads of ≥5.1 log copies/mL had an extremely high mortality in the Brazilian experience [<a href="#rid47">47</a>]. This phase is characterized by variable dysfunction of multiple organs including the liver, kidneys, and cardiovascular system. Multiorgan failure in yellow fever is associated with high levels of proinflammatory cytokines similar to that seen in bacterial sepsis and systemic immune response syndrome (SIRS) [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H9"><span class="h3">Hepatic dysfunction</span><span class="headingEndMark"> — </span>Hepatic dysfunction due to yellow fever differs from other viral hepatitides in that serum aspartate aminotransferase (AST) levels exceed those of alanine aminotransferase (ALT). This may be due to concomitant viral injury to the myocardium and skeletal muscle. The levels are proportional to disease severity. In one study, the mean AST and ALT levels in fatal cases were 2766 and 660 U, respectively, while in surviving patients with jaundice, the mean levels were 929 and 351 U [<a href="#rid48">48</a>]. Alkaline phosphatase levels are normal or only slightly elevated. Direct bilirubin levels are typically between 5 and 10 mg/dL, with higher levels in fatal than in nonfatal cases [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H10"><span class="h3">Renal dysfunction</span><span class="headingEndMark"> — </span>Renal damage is characterized by oliguria, azotemia, and very high levels of protein in the urine. Serum creatinine levels are three to eight times normal. In some patients who survive the hepatitic phase, renal failure predominates [<a href="#rid50">50</a>]. Death is preceded by virtually complete anuria.</p><p class="headingAnchor" id="H11"><span class="h3">Hemorrhage</span><span class="headingEndMark"> — </span>Hemorrhage is a prominent component of the third phase of illness, including coffee-grounds hematemesis, melena, hematuria, metrorrhagia, petechiae, ecchymoses, epistaxis, oozing of blood from the gums, and bleeding from needle puncture sites. Gastrointestinal hemorrhage may contribute to circulatory collapse. Laboratory abnormalities include thrombocytopenia, prolonged prothrombin time, and global reductions in clotting factors synthesized by the liver (factors II, V, VII, IX, and X). Some patients have findings suggesting disseminated intravascular coagulation, including diminished fibrinogen and factor VIII and the presence of fibrin split products.</p><p class="headingAnchor" id="H12"><span class="h3">Myocardial injury</span><span class="headingEndMark"> — </span>The clinical significance of myocardial injury is poorly understood and probably has been underestimated in clinical studies. In some cases, acute cardiac enlargement has been documented during the course of infection [<a href="#rid51">51</a>]. The electrocardiogram may show sinus bradycardia without conduction defects, ST-T abnormalities, particularly elevated T waves, and extrasystoles [<a href="#rid52">52</a>]. Bradycardia and myocarditis may contribute to hypotension, reduced perfusion, and metabolic acidosis in severe cases. Arrhythmia has been suggested to explain the rare reports of late death during convalescence.</p><p class="headingAnchor" id="H13"><span class="h3">Central nervous system dysfunction</span><span class="headingEndMark"> — </span>Patients exhibit variable signs of central nervous system (CNS) dysfunction including delirium, agitation, convulsions, stupor, and coma. In severe cases, the cerebrospinal fluid is under increased pressure and may contain elevated protein but no cells. Pathologic changes include microscopic perivascular hemorrhages and edema. Given the absence of inflammatory changes suggesting viral neuroinvasion and encephalitis, CNS alterations are probably due to metabolic encephalopathy. True yellow fever viral encephalitis is exceedingly rare.</p><p class="headingAnchor" id="H4048000818"><span class="h3">Pancreatitis</span><span class="headingEndMark"> — </span>Among patients with severe yellow fever reported from the 2018 Brazilian epidemic, the incidence of pancreatitis was 58 percent [<a href="#rid26">26</a>]. </p><p class="headingAnchor" id="H14"><span class="h2">Outcome</span><span class="headingEndMark"> — </span>The outcome is determined during the second week after onset, at which point the patient either dies or rapidly recovers. Approximately 20 to 50 percent of patients who enter the period of intoxication succumb to the disease. Poor prognostic signs include anuria, shock, hypothermia, agitation, delirium, intractable hiccups, seizures, hypoglycemia, hyperkalemia, metabolic acidosis, Cheyne-Stokes respirations, stupor, and coma. A study in a tertiary hospital setting in Brazil identified the following predictive factors for progression to severe yellow fever: older age, male sex, elevated leukocyte and neutrophil counts, elevated alanine aminotransferase, aspartate transaminase (AST), bilirubin, creatinine, prolonged prothrombin time, and higher yellow fever virus RNA plasma viral load. In a multivariate regression model, older age, elevated neutrophil count, increased AST, and higher viral load were independently associated with death [<a href="#rid47">47</a>].</p><p>Convalescence may be associated with fatigue lasting for several weeks. In some cases, jaundice and serum transaminase elevations may persist for months, although such patients may have yellow fever superimposed on other hematologic or hepatic diseases. The outcome of yellow fever appears to be comparable in patients with or without hepatitis B surface antigenemia.</p><p>Complications of yellow fever include bacterial superinfections, such as pneumonia, parotitis, and sepsis. Late deaths during convalescence occur rarely and have been attributed to myocarditis, arrhythmia, or heart failure.</p><p class="headingAnchor" id="H15"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Diagnosis is made by serology, detection of viral genome by polymerase chain reaction (PCR), by viral isolation or histopathology, and immunohistochemistry on postmortem tissues.</p><p class="headingAnchor" id="H16"><span class="h2">Serology</span><span class="headingEndMark"> — </span>Serologic diagnosis is best accomplished using an enzyme-linked immunosorbent assay (ELISA) for immunoglobulin (Ig)M. The presence of IgM antibodies in a single sample provides a presumptive diagnosis; confirmation is made by a rise in titer between paired acute and convalescent samples or a fall between early and late convalescent samples.</p><p>Persistence of antibodies from earlier receipt of the live-attenuated vaccine can complicate interpretation of IgM results [<a href="#rid53">53</a>]. In addition, cross-reactions with other flaviviruses complicate the diagnosis of yellow fever by serologic methods, particularly in Africa where multiple flaviviruses circulate. The neutralization test is more specific but requires a specialized laboratory.</p><p class="headingAnchor" id="H17"><span class="h2">Rapid diagnostic tests</span><span class="headingEndMark"> — </span>Rapid diagnostic tests include PCR to detect viral genome in the blood or tissue and ELISA for determination of IgM antibody [<a href="#rid10">10</a>]. Next-generation sequencing of RNA directly amplified from blood has been used to confirm the diagnosis and compare the patient’s strain to known geographic clades of the virus. These tools are increasingly available in national and regional laboratories in the endemic areas. A reverse-transcription loop-mediated isothermal amplification (RT-LAMP) yellow fever diagnostic test, which does not require thermocycling equipment and can be read visually, has shown promise as a sensitive and rapid test for use in field conditions [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H18"><span class="h2">Virus isolation</span><span class="headingEndMark"> — </span>Virus isolation is accomplished by inoculation of mosquito or mammalian cell cultures, intracerebral inoculation of suckling mice, or intrathoracic inoculation of mosquitoes. The virus may also be recovered from postmortem liver tissue. During a yellow fever outbreak in Ivory Coast in 1982 including 90 confirmed cases, 30 percent were diagnosed by virus isolation from the blood; the majority of patients had detectable virus prior to onset of jaundice [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H19"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>Liver biopsy during illness due to yellow fever should never be performed, since fatal hemorrhage may ensue. Postmortem histopathologic examination of the liver often demonstrates the typical features of yellow fever including midzonal necrosis. A definitive postmortem diagnosis may be made by immunocytochemical staining for yellow fever antigen in the liver, heart, spleen, or kidney [<a href="#rid56">56-58</a>]. (See <a class="local">'Virology, pathogenesis, and histopathology'</a> above.)</p><p class="headingAnchor" id="H5389867"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of yellow fever includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Viral hepatitis (hepatitis A, B, C, D, and E) – These entities are characterized by elevated transaminases; hepatitis A and E are acute infections transmitted most frequently by the fecal-oral route, whereas hepatitis B, C, and D can present acutely or chronically and are transmitted by body fluids. In Africa, severe and fatal hepatitis E in pregnancy has frequently been misdiagnosed as yellow fever. (See related topics.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Influenza – Influenza is associated with fever, headache, malaise, and myalgias. It is not generally associated with severe hepatic involvement or jaundice. The diagnosis is established by viral detection. (See  <a class="medical medical_review" href="/d/html/7004.html" rel="external">"Seasonal influenza in adults: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dengue – Dengue and yellow fever are similar in that both are associated with fever, headache and body aches, and hemorrhagic manifestations. Hepatic involvement can occur in the setting of severe dengue infection [<a href="#rid59">59</a>]. The diagnosis of dengue is established by serology. (See  <a class="medical medical_review" href="/d/html/3025.html" rel="external">"Dengue virus infection: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malaria – Malaria is characterized by fever and anemia; clinical manifestations include jaundice due to hemolysis. The diagnosis of malaria is established by visualization of parasites on peripheral smear. (See  <a class="medical medical_review" href="/d/html/5709.html" rel="external">"Malaria: Clinical manifestations and diagnosis in nonpregnant adults and children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Typhoid – Manifestations of typhoid fever include fever and gastrointestinal symptoms. Abnormal liver function tests are observed but jaundice is not a typical clinical feature. The diagnosis is established by culture. (See  <a class="medical medical_review" href="/d/html/2708.html" rel="external">"Enteric (typhoid and paratyphoid) fever: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Leptospirosis – Leptospirosis is a bacterial infection characterized by fever, myalgia, headache, and conjunctival suffusion. Modest elevation of hepatic transaminases may be observed. The diagnosis is established by serology. (See  <a class="medical medical_review" href="/d/html/5527.html" rel="external">"Leptospirosis: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Q fever – Q fever occurs as a result of infection with <em>Coxiella burnetii</em>; hepatic involvement includes elevated transaminases, hepatomegaly without jaundice, and granulomas on liver biopsy. The diagnosis is established by serology.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemorrhagic fever – Yellow fever may be distinguished from other viral hemorrhagic fevers (Lassa fever, Marburg virus, Ebola virus, Bolivian and Argentine hemorrhagic fevers) in that these other viral hemorrhagic fevers are not usually associated with jaundice. However, Congo-Crimean hemorrhagic fever may be associated with severe liver damage; Rift Valley fever and dengue hemorrhagic fever may present with this complication as well. (See related topics.)</p><p></p><p class="headingAnchor" id="H32"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Yellow fever is a mosquito-borne viral hemorrhagic fever with a high case-fatality rate. Travelers to tropical regions of South America and sub-Saharan Africa are at risk for acquisition of infection and require immunization. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mosquito-borne epidemics in Africa occur where human populations reside in high density and immunization coverage is low (so-called "urban yellow fever"). Fewer cases occur in South America than in Africa because transmission occurs principally from monkey to human via mosquito vectors, the vector density is relatively low, and vaccination coverage is relatively high (so-called "jungle yellow fever"). (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Yellow fever is characterized by three stages: periods of infection, remission, and intoxication. The period of infection consists of viremia with nonspecific symptoms and signs including fever, malaise, headache, joint pain, nausea, and vomiting. This is followed by a period of remission with abatement of fever and symptoms lasting up to 48 hours. The subsequent period of intoxication is characterized by hepatic dysfunction, renal failure, coagulopathy, and shock. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis may be made by serology, by detection of viral genome by polymerase chain reaction in serum, by virus isolation, or by histopathology and immunocytochemistry (postmortem samples only). Serologic diagnosis is best accomplished using an enzyme-linked immunosorbent assay for immunoglobulin (Ig)M. The presence of IgM antibodies in a single sample provides a presumptive diagnosis; confirmation is made by a rise in titer between paired acute and convalescent samples or a fall between early and late convalescent samples. More specific neutralization tests may be performed but require a specialized laboratory. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H2397150718"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Thomas Monath, MD, FACP, FASTMH, and Edward T Ryan, MD, DTMH, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mutebi JP, Wang H, Li L, et al. Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa. J Virol 2001; 75:6999.</a></li><li><a class="nounderline abstract_t">Vasconcelos PF, Bryant JE, da Rosa TP, et al. Genetic divergence and dispersal of yellow fever virus, Brazil. Emerg Infect Dis 2004; 10:1578.</a></li><li><a class="nounderline abstract_t">Chen C, Jiang D, Ni M, et al. Phylogenomic analysis unravels evolution of yellow fever virus within hosts. PLoS Negl Trop Dis 2018; 12:e0006738.</a></li><li><a class="nounderline abstract_t">Moreira-Soto A, Torres MC, Lima de Mendonça MC, et al. Evidence for multiple sylvatic transmission cycles during the 2016-2017 yellow fever virus outbreak, Brazil. Clin Microbiol Infect 2018; 24:1019.e1.</a></li><li><a class="nounderline abstract_t">Dennis LH, Reisberg BE, Crosbie J, et al. The original haemorrhagic fever: yellow fever. Br J Haematol 1969; 17:455.</a></li><li><a class="nounderline abstract_t">Tigertt WD, Berge TO, Gochenour WS, et al. Experimental yellow fever. Trans N Y Acad Sci 1960; 22:323.</a></li><li><a class="nounderline abstract_t">Monath TP, Brinker KR, Chandler FW, et al. Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues. Am J Trop Med Hyg 1981; 30:431.</a></li><li><a class="nounderline abstract_t">Monath TP, Barrett AD. Pathogenesis and pathophysiology of yellow fever. Adv Virus Res 2003; 60:343.</a></li><li><a class="nounderline abstract_t">Quaresma JA, Barros VL, Fernandes ER, et al. Reconsideration of histopathology and ultrastructural aspects of the human liver in yellow fever. Acta Trop 2005; 94:116.</a></li><li><a class="nounderline abstract_t">Bae HG, Drosten C, Emmerich P, et al. Analysis of two imported cases of yellow fever infection from Ivory Coast and The Gambia to Germany and Belgium. J Clin Virol 2005; 33:274.</a></li><li><a class="nounderline abstract_t">Quaresma JA, Barros VL, Pagliari C, et al. Revisiting the liver in human yellow fever: virus-induced apoptosis in hepatocytes associated with TGF-beta, TNF-alpha and NK cells activity. Virology 2006; 345:22.</a></li><li><a class="nounderline abstract_t">Quaresma JA, Barros VL, Fernandes ER, et al. Immunohistochemical examination of the role of Fas ligand and lymphocytes in the pathogenesis of human liver yellow fever. Virus Res 2006; 116:91.</a></li><li><a class="nounderline abstract_t">ter Meulen J, Sakho M, Koulemou K, et al. Activation of the cytokine network and unfavorable outcome in patients with yellow fever. J Infect Dis 2004; 190:1821.</a></li><li><a class="nounderline abstract_t">Hughes TP. Precipiten reaction in yellow fever. J Immunol 1933; 25:275.</a></li><li><a class="nounderline abstract_t">Tesh RB, Guzman H, da Rosa AP, et al. Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J Infect Dis 2001; 183:1431.</a></li><li><a class="nounderline abstract_t">Xiao SY, Zhang H, Guzman H, Tesh RB. Experimental yellow fever virus infection in the Golden hamster (Mesocricetus auratus). II. Pathology. J Infect Dis 2001; 183:1437.</a></li><li><a class="nounderline abstract_t">Meier KC, Gardner CL, Khoretonenko MV, et al. A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog 2009; 5:e1000614.</a></li><li><a class="nounderline abstract_t">Monath TP. Yellow fever: Victor, Victoria? Conqueror, conquest? Epidemics and research in the last forty years and prospects for the future. Am J Trop Med Hyg 1991; 45:1.</a></li><li><a class="nounderline abstract_t">Robertson SE, Hull BP, Tomori O, et al. Yellow fever: a decade of reemergence. JAMA 1996; 276:1157.</a></li><li><a class="nounderline abstract_t">Monath TP. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines 2012; 11:427.</a></li><li><a class="nounderline abstract_t">Garske T, Van Kerkhove MD, Yactayo S, et al. Yellow Fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med 2014; 11:e1001638.</a></li><li class="breakAll">ProMED mail. Yellow fever - Countries with dengue: Alert. http://promedmail.org/post/20160328.4123983 (Accessed on April 05, 2016).</li><li><a class="nounderline abstract_t">Otshudiema JO, Ndakala NG, Mawanda EK, et al. Yellow Fever Outbreak - Kongo Central Province, Democratic Republic of the Congo, August 2016. MMWR Morb Mortal Wkly Rep 2017; 66:335.</a></li><li><a class="nounderline abstract_t">Bagcchi S. Looking back at yellow fever in Angola. Lancet Infect Dis 2017; 17:269.</a></li><li><a class="nounderline abstract_t">Gómez MM, Abreu FVS, Santos AACD, et al. Genomic and structural features of the yellow fever virus from the 2016-2017 Brazilian outbreak. J Gen Virol 2018; 99:536.</a></li><li><a class="nounderline abstract_t">Ho YL, Joelsons D, Leite GFC, et al. Severe yellow fever in Brazil: clinical characteristics and management. J Travel Med 2019; 26.</a></li><li><a class="nounderline abstract_t">Blake LE, Garcia-Blanco MA. Human genetic variation and yellow fever mortality during 19th century U.S. epidemics. MBio 2014; 5:e01253.</a></li><li><a class="nounderline abstract_t">Wilder-Smith A, Leong WY. Importation of yellow fever into China: assessing travel patterns. J Travel Med 2017; 24.</a></li><li><a class="nounderline abstract_t">McFarland JM, Baddour LM, Nelson JE, et al. Imported yellow fever in a United States citizen. Clin Infect Dis 1997; 25:1143.</a></li><li><a class="nounderline abstract_t">Barros ML, Boecken G. Jungle yellow fever in the central Amazon. Lancet 1996; 348:969.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Fatal yellow fever in a traveler returning from Venezuela, 1999. MMWR Morb Mortal Wkly Rep 2000; 49:303.</a></li><li><a class="nounderline abstract_t">Colebunders R, Mariage JL, Coche JC, et al. A Belgian traveler who acquired yellow fever in the Gambia. Clin Infect Dis 2002; 35:e113.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Fatal yellow fever in a traveler returning from Amazonas, Brazil, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:324.</a></li><li><a class="nounderline abstract_t">Wilder-Smith A, Massad E. Estimating the number of unvaccinated Chinese workers against yellow fever in Angola. BMC Infect Dis 2018; 18:185.</a></li><li><a class="nounderline abstract_t">Hamer DH, Angelo K, Caumes E, et al. Fatal Yellow Fever in Travelers to Brazil, 2018. MMWR Morb Mortal Wkly Rep 2018; 67:340.</a></li><li class="breakAll">World Health Organization. Epidemiological Update - Yellow Fever - 20 March 2018. http://www.paho.org/hq/index.php?option=com_docman&amp;task=doc_view&amp;Itemid=270&amp;gid=44111&amp;lang=en (Accessed on March 22, 2018).</li><li class="breakAll">World Health Organization. Yellow fever - Brazil. https://www.who.int/emergencies/disease-outbreak-news/item/18-april-2019-yellow-fever-brazil-en (Accessed on February 01, 2022).</li><li class="breakAll">https://wwwnc.cdc.gov/travel/page/yellow-fever-information (Accessed on March 22, 2018).</li><li class="breakAll">https://wwwnc.cdc.gov/travel/notices/alert/yellow-fever-brazil (Accessed on March 22, 2018).</li><li class="breakAll">https://www.cdc.gov/media/releases/2018/s0316-yellow-fever-brazil.html (Accessed on March 22, 2018).</li><li class="breakAll">Pan American Health Organization. Epidemiological update yellow fever. https://www.paho.org/hq/index.php?option=com_docman&amp;view=download&amp;category_slug=yellow-fever-2194&amp;alias=47954-6-march-2019-yellow-fever-epidemiological-update&amp;Itemid=270&amp;lang=en (Accessed on August 26, 2019).</li><li><a class="nounderline abstract_t">Outbreak news. Yellow fever, Paraguay. Wkly Epidemiol Rec 2008; 83:105.</a></li><li><a class="nounderline abstract_t">Monath TP. Yellow fever: a medically neglected disease. Report on a seminar. Rev Infect Dis 1987; 9:165.</a></li><li><a class="nounderline abstract_t">Johansson MA, Arana-Vizcarrondo N, Biggerstaff BJ, Staples JE. Incubation periods of Yellow fever virus. Am J Trop Med Hyg 2010; 83:183.</a></li><li><a class="nounderline abstract_t">Barnett ED. Yellow fever: epidemiology and prevention. Clin Infect Dis 2007; 44:850.</a></li><li><a class="nounderline abstract_t">Tuboi SH, Costa ZG, da Costa Vasconcelos PF, Hatch D. Clinical and epidemiological characteristics of yellow fever in Brazil: analysis of reported cases 1998-2002. Trans R Soc Trop Med Hyg 2007; 101:169.</a></li><li><a class="nounderline abstract_t">Kallas EG, D'Elia Zanella LGFAB, Moreira CHV, et al. Predictors of mortality in patients with yellow fever: an observational cohort study. Lancet Infect Dis 2019; 19:750.</a></li><li><a class="nounderline abstract_t">Oudart JL, Rey M. [Proteinuria, proteinaemia, and serum transaminase activity in 23 confirmed cases of yellow fever]. Bull World Health Organ 1970; 42:95.</a></li><li><a class="nounderline abstract_t">ELTON NW, ROMERO A, TREJOS A. Clinical pathology of yellow fever. Am J Clin Pathol 1955; 25:135.</a></li><li><a class="nounderline abstract_t">Lopes RL, Pinto JR, Silva Junior GBD, et al. Kidney involvement in yellow fever: a review. Rev Inst Med Trop Sao Paulo 2019; 61:e35.</a></li><li><a class="nounderline abstract_t">Berry GP, Kitchen SF. Yellow fever accidentally contracted in the laboratory: A study of seven cases. Am J Trop Med Hyg 1931; 11:365.</a></li><li><a class="nounderline abstract_t">Paixão GMM, Nunes MCP, Beato BDVG, et al. Cardiac Involvement by Yellow Fever(from the PROVAR+ Study). Am J Cardiol 2019; 123:833.</a></li><li><a class="nounderline abstract_t">Gibney KB, Edupuganti S, Panella AJ, et al. Detection of anti-yellow fever virus immunoglobulin m antibodies at 3-4 years following yellow fever vaccination. Am J Trop Med Hyg 2012; 87:1112.</a></li><li><a class="nounderline abstract_t">Nunes MR, Vianez JL Jr, Nunes KN, et al. Analysis of a Reverse Transcription Loop-mediated Isothermal Amplification (RT-LAMP) for yellow fever diagnostic. J Virol Methods 2015; 226:40.</a></li><li><a class="nounderline abstract_t">Lhuillier M, Sarthou JL, Cordellier R, et al. [Rural epidemic of yellow fever with interhuman transmission in the Ivory Coast in 1982]. Bull World Health Organ 1985; 63:527.</a></li><li><a class="nounderline abstract_t">Monath TP, Ballinger ME, Miller BR, Salaun JJ. Detection of yellow fever viral RNA by nucleic acid hybridization and viral antigen by immunocytochemistry in fixed human liver. Am J Trop Med Hyg 1989; 40:663.</a></li><li><a class="nounderline abstract_t">Vieira WT, Gayotto LC, de Lima CP, de Brito T. Histopathology of the human liver in yellow fever with special emphasis on the diagnostic role of the Councilman body. Histopathology 1983; 7:195.</a></li><li><a class="nounderline abstract_t">De Brito T, Siqueira SA, Santos RT, et al. Human fatal yellow fever. Immunohistochemical detection of viral antigens in the liver, kidney and heart. Pathol Res Pract 1992; 188:177.</a></li><li><a class="nounderline abstract_t">Wilder-Smith A, Ooi EE, Horstick O, Wills B. Dengue. Lancet 2019; 393:350.</a></li></ol></div><div id="topicVersionRevision">Topic 3032 Version 58.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11435580" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15498159" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Genetic divergence and dispersal of yellow fever virus, Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30188905" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Phylogenomic analysis unravels evolution of yellow fever virus within hosts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29427798" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Evidence for multiple sylvatic transmission cycles during the 2016-2017 yellow fever virus outbreak, Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4981419" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The original haemorrhagic fever: yellow fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Experimental yellow fever</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7235133" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14689698" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pathogenesis and pathophysiology of yellow fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15829426" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Reconsideration of histopathology and ultrastructural aspects of the human liver in yellow fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16036176" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Analysis of two imported cases of yellow fever infection from Ivory Coast and The Gambia to Germany and Belgium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16278000" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Revisiting the liver in human yellow fever: virus-induced apoptosis in hepatocytes associated with TGF-beta, TNF-alpha and NK cells activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16219382" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Immunohistochemical examination of the role of Fas ligand and lymphocytes in the pathogenesis of human liver yellow fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15499539" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Activation of the cytokine network and unfavorable outcome in patients with yellow fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Precipiten reaction in yellow fever</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11319679" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11319680" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Experimental yellow fever virus infection in the Golden hamster (Mesocricetus auratus). II. Pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19816561" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A mouse model for studying viscerotropic disease caused by yellow fever virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1867343" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Yellow fever: Victor, Victoria? Conqueror, conquest? Epidemics and research in the last forty years and prospects for the future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8827969" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Yellow fever: a decade of reemergence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22551029" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Review of the risks and benefits of yellow fever vaccination including some new analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24800812" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Yellow Fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24800812" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Yellow Fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28358796" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Yellow Fever Outbreak - Kongo Central Province, Democratic Republic of the Congo, August 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28244394" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Looking back at yellow fever in Angola.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29469689" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Genomic and structural features of the yellow fever virus from the 2016-2017 Brazilian outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31150098" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Severe yellow fever in Brazil: clinical characteristics and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24895309" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Human genetic variation and yellow fever mortality during 19th century U.S. epidemics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28426111" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Importation of yellow fever into China: assessing travel patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9402373" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Imported yellow fever in a United States citizen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8843848" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Jungle yellow fever in the central Amazon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10825087" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Fatal yellow fever in a traveler returning from Venezuela, 1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12410495" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A Belgian traveler who acquired yellow fever in the Gambia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11990236" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Fatal yellow fever in a traveler returning from Amazonas, Brazil, 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29665797" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Estimating the number of unvaccinated Chinese workers against yellow fever in Angola.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29565840" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Fatal Yellow Fever in Travelers to Brazil, 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29565840" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Fatal Yellow Fever in Travelers to Brazil, 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29565840" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Fatal Yellow Fever in Travelers to Brazil, 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29565840" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Fatal Yellow Fever in Travelers to Brazil, 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29565840" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Fatal Yellow Fever in Travelers to Brazil, 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29565840" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Fatal Yellow Fever in Travelers to Brazil, 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29565840" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Fatal Yellow Fever in Travelers to Brazil, 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18350685" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Outbreak news. Yellow fever, Paraguay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3547569" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Yellow fever: a medically neglected disease. Report on a seminar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20595499" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Incubation periods of Yellow fever virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17304460" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Yellow fever: epidemiology and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16814821" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical and epidemiological characteristics of yellow fever in Brazil: analysis of reported cases 1998-2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31104909" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Predictors of mortality in patients with yellow fever: an observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5309915" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : [Proteinuria, proteinaemia, and serum transaminase activity in 23 confirmed cases of yellow fever].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14349922" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clinical pathology of yellow fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31340247" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Kidney involvement in yellow fever: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Yellow fever accidentally contracted in the laboratory: A study of seven cases</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30545483" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cardiac Involvement by Yellow Fever(from the PROVAR+ Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23109371" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Detection of anti-yellow fever virus immunoglobulin m antibodies at 3-4 years following yellow fever vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26459206" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Analysis of a Reverse Transcription Loop-mediated Isothermal Amplification (RT-LAMP) for yellow fever diagnostic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2994899" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : [Rural epidemic of yellow fever with interhuman transmission in the Ivory Coast in 1982].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2500857" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Detection of yellow fever viral RNA by nucleic acid hybridization and viral antigen by immunocytochemistry in fixed human liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6303935" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Histopathology of the human liver in yellow fever with special emphasis on the diagnostic role of the Councilman body.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1594489" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Human fatal yellow fever. Immunohistochemical detection of viral antigens in the liver, kidney and heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30696575" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Dengue.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
